Death-associated protein kinase is essential for the survival of various types of uterine cancer cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 1017-1022

  Tanaka, Tetsuji ^a   Bai, Tao ^a   Yukawa, Kazunori ^b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Death associated protein kinase; Endometrial adenocarcinoma; siRNA; Uterine carcinosarcoma; Uterine leiomyosarcoma

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; PROTEIN BCL 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOSARCOMA; CELL DEATH; CELL IMMORTALIZATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS CANCER;

EID: 77956547063     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000753     Document Type: Article

References (33)

1. Deiss LP, Feinstein E, Berissi H, Cohen O and Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kDa protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9: 15-30, 1995.
2. 2+/ calmodulin-dependent, cytoskeleton-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16: 998-1008, 1997.
3. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak- Kroizaman T, Feinstein E and Kimchi A: DAP kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146: 141-148, 1999.
4. Jang CW, Chen CH, Chen CC, Chen JY, Su YH and Chen RH: TGFβ induces apoptosis through Smad-mediated expression of DAP kinase. Nat Cell Biol 4: 51-58, 2002.
5. Raveh T, Droguett G, Horwitz MS, De Pinho RA and Kimchi A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7, 2001. (Pubitemid 32114825)
6. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH and Kimchi A: Death-associated protein (DAP) kinase plays a central role in ceramide induced apoptosis in cultured hippocampal neurons. J Biol Chem 277: 1957-1961, 2002.
7. Yamamoto M, Hioki T, Nakajima-Iijima S and Uchino S: DAP kinase activity is critical for C (2)-ceramide-induced apoptosis in PC12 cells. Eur J Biochem 269: 139-147, 2002.
8. Wang WJ, Kuo JC, Yao CC and Chen RH: DAP kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159: 169-179, 2002.
9. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, Eydmann ME and Kimchi A: DAP kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15: 403-407, 1997.
10. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L and Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature 390: 180-184, 1997.
11. Jin Y, Blue EK, Dixon S, Hou L, Wysolmerski RB and Gallagher PJ: Identification of a new form of death-associated protein kinase that promotes cell survival. J Biol Chem 276: 39667-39678, 2001.
12. Jin Y and Gallagher PJ: Antisense depletion of death-associated protein kinase promotes apoptosis. J Biol Chem 278: 51587-51593, 2003. (Pubitemid 38020402)
13. Bai T, Tanaka T, Yukawa K, Maeda M and Umesaki N: Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol Rep 11: 661-665, 2004.
14. Ishiwata I, Ishiwata C, Soma M, Arai J and Ishikawa H: Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesteron receptors. Gynecol Oncol 17: 281-290, 1984.
15. Bai T, Tanaka T and Yukawa K: Targeted knockdown of death-associated protein kinase expression induces TRAIL-mediated apoptosis in human endometrial adenocarcinoma cells. Int J Oncol 37: 203-210, 2010.
16. Satyaswaroop PG, Frost A and Gurpide E: Metabolism and effects of progesterone in the human endometrial adenocarcinoma cell line HEC-1. Steroids 35: 21-37, 1980.
17. Motoyama T: Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers. Acta Obstet Gynecol Jpn 33: 1197-1204, 1981.
18. Kidera Y, Yoshimura T, Ohkuma Y, Iwasaka T and Sugimori H: Establishment and characterization of a cell line derived from mucinous cystadenocarcinoma of human ovary. Acta Obstet Gynecol Jpn 37: 1820-1824, 1985.
19. Hsu SH, Schacter BZ, Delaney NL, Miller TB, McKusick VA, Kennett RH, Bodmer JG, Young D and Bodmer WF: Genetic characteristics of the HeLa cell. Science 191: 292-394, 1976.
20. Ishiwata I, Nozawa S, Nagai S, Kurihara S and Mikata A: Establishment of a human leiomyosarcoma cell line. Cancer Res 37: 658-664, 1977.
21. Ishiwata I, Ishiwata C, Soma M, Iguchi M, Kiguchi K, Tamagawa T, Ishiwata I and Ishikawa H: Histogenesis of carcinosarcoma and establishment of leiomyosarcoma cell line (HTMMT) derived from human uterine carcinosarcoma. Hum Cell 17: 131-137, 2004.
22. Nishida M, Kasahara K, Kaneko M, Iwasaki H and Hayashi K: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynecol Jpn 37: 1103-1111, 1985.
23. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420, 1994.
24. Del Bino G, Darzynkiewicz Z, Degraef C, Mosselmans R, Fokan D and Galand P: Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Cell Prolif 32: 25-37, 1999.
25. Miller DL and Dou C: Induction of apoptosis in sonoporation and ultrasonic gene transfer. Ultrasound Med Biol 35: 144-154, 2009.
26. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, Eydmann ME and Kimchi A: DAP kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15: 403-407, 1997.
27. Nakatsuka S, Takakuwa T, Tomita Y, Miwa H, Matsuzuka F and Aozasa K: Role of hypermethylation of DAP kinase CpG island in the development of thyroid lymphoma. Lab Invest 80: 1651-1655, 2000.
28. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895, 2000.
29. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999.
30. Katzenellenbogen RA, Baylin SB and Herman JG: Hypermethylation of the DAP kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353, 1999.
31. Lee TL, Leung WK, Chan M WY, Ng EKW, Tong JHM, Lo KW, Chung SCS, Sung JJY and To KF: Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8: 1761-1766, 2002.
32. Satoh A, Toyota M, Itoh F, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T and Imai K: DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 86: 1817-1823, 2002.
33. Dong SM, Kim HS, Rha SH and Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7: 1982-1986, 2001.